Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2017-08-14 Earnings Release
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG: Biotest reported sales of EUR 247.1 million in the first half of 2017
Earnings Release Classification · 100% confidence The document explicitly states it contains results for the 'first half of 2017' and discusses revenue, EBIT, and EAT for this period. It also mentions the 'half-year-report 2017' is available on the company website. This content structure—a summary of financial performance for a period shorter than a year—is characteristic of an Interim/Quarterly Report. Although it is presented as a news release (DGAP-News), the core content is the financial summary, making 'IR' (Interim / Quarterly Report) the most appropriate classification over 'ER' (Earnings Release, which is usually just highlights) or 'RPA' (since it contains the actual summarized results, not just an announcement of a separate report). The length (8253 chars) is substantial enough to contain more than just an announcement. H1 2017
2017-08-14 English
Datum:14.08.2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halbjahresbericht 2017' (Half-Year Report 2017) for Biotest AG. It contains comprehensive financial data, including a balance sheet, income statement, segment reporting, and a detailed management discussion (Konzernzwischenlagebericht) for the first six months of the fiscal year. It is not an announcement of a report, but the report itself, containing substantive financial analysis and data for an interim period. H1 2017
2017-08-14 German
Half-yearly financial report 2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-Year Report 2017' for Biotest AG. It contains comprehensive financial statements (Consolidated statement of income, financial position, cash flow, etc.), an interim management report, and detailed business performance analysis for the first six months of the fiscal year. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2017
2017-08-14 German
Datum:25.07.2017
Board/Management Information Classification · 100% confidence The document is a 'Bericht des Aufsichtsrats' (Supervisory Board Report) for Biotest AG for the fiscal year 2016. This report is a mandatory component of the German Annual Report (Jahresabschluss) package, detailing the board's activities, committee meetings, and oversight of the management board. While it is a specific section of the annual reporting suite, it functions as part of the comprehensive annual financial disclosure. Given the definitions provided, it aligns best with the 'Annual Report' (10-K) category as it represents the official yearly governance and oversight reporting.
2017-07-25 German
Biotest Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 30.08.2017 in Frankfurt am Main mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 100% confidence The document is explicitly titled 'Einladung zur ordentlichen Hauptversammlung 2017' (Invitation to the Annual General Meeting 2017) and contains the agenda ('Tagesordnung') for this meeting, including proposals for dividend approval, discharge of board members, election of auditors, election of supervisory board members, and capital structure changes. The German term 'Hauptversammlung' directly translates to Annual General Meeting (AGM). This content aligns perfectly with the definition for AGM Information (AGM-R). It is an announcement/invitation for the meeting, not the voting results (DVA) or a general presentation (IP).
2017-07-20 German
Biotest AG: Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic
M&A Activity Classification · 99% confidence The document is a press release dated July 19, 2017, announcing that Biotest AG has taken over Cara Plasma s.r.o. This transaction involves corporate activity related to securing plasma supply, which falls under strategic business changes or M&A activity. Since the core event is the acquisition of a supplier, it aligns best with the 'M&A Activity' category (TAR). It is not a standard financial report (10-K, IR, ER) nor a management change (MANG) or financing event (CAP). Given the nature of the acquisition, TAR is the most appropriate fit.
2017-07-19 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.